SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precision Autophagy Inhibition

Executive Summary: SAR405 (A8883, APExBIO) is a low nanomolar ATP-competitive inhibitor of Vps34, a class III PI3K isoform critical for autophagy and vesicle trafficking (product page). It is highly selective, showing a Kd of 1.5 nM and an IC₅₀ of 1 nM for human Vps34, without inhibiting class I/II PI3Ks or mTOR at concentrations up to 10 μM (APExBIO). SAR405 blocks autophagosome formation and impairs endosome-lysosome function, making it a robust tool for dissecting autophagy mechanisms (Park et al., 2023). It has advanced solubility and storage parameters, ensuring experimental reproducibility (APExBIO). The compound's specificity and mechanistic action are essential for studies in cancer biology, neurodegeneration, and vesicle trafficking (Related Analysis).

Biological Rationale

Autophagy is a conserved cellular process for degradation and recycling of cytoplasmic components, supporting homeostasis during nutrient deprivation and stress (Park et al., 2023). Vps34, the only class III phosphoinositide 3-kinase in mammals, is essential for autophagosome nucleation and vesicle trafficking. Pharmacological inhibition of Vps34 disrupts autophagy initiation, impacting disease-relevant pathways in cancer and neurodegeneration. Specific inhibition of Vps34, rather than broad PI3K/mTOR targeting, enables precise mechanistic dissection of the autophagy process.

Mechanism of Action of SAR405

SAR405 acts as a highly potent, ATP-competitive inhibitor, binding selectively within the ATP-binding cleft of recombinant human Vps34 (class III PI3K). The compound exhibits a Kd of 1.5 nM and an IC₅₀ of 1 nM for Vps34 kinase activity. At concentrations up to 10 μM, SAR405 does not inhibit class I or class II PI3Ks, nor mTOR, confirming its selectivity (APExBIO).

Upon Vps34 inhibition, SAR405 blocks the generation of phosphatidylinositol 3-phosphate (PI3P), a lipid required for autophagosome membrane nucleation. This results in impaired autophagosome formation, accumulation of swollen late endosome-lysosomes, and defective cathepsin D maturation. In cell assays (e.g., GFP-LC3 HeLa, H1299 cells), SAR405 abrogates autophagic flux and synergizes with mTOR inhibitors such as everolimus, enabling dual pathway dissection (Park et al., 2023).

Evidence & Benchmarks

• SAR405 inhibits human recombinant Vps34 with an IC₅₀ of 1 nM and Kd of 1.5 nM, as determined by enzymatic assays (APExBIO).
• Does not inhibit class I/II PI3Ks or mTOR at concentrations up to 10 μM, ensuring target specificity (APExBIO).
• Prevents autophagosome formation and autophagy in GFP-LC3 HeLa and H1299 cell lines under nutrient deprivation (Park et al., 2023).
• Combining SAR405 with mTOR inhibitors (e.g., everolimus) yields synergistic inhibition of autophagy, highlighting distinct pathway contributions (Park et al., 2023).
• Disrupts late endosome-lysosome function, causing accumulation of swollen organelles and impaired cathepsin D maturation (APExBIO).
• Soluble in DMSO (>10 mM), insoluble in water, and soluble in ethanol with ultrasonic assistance, facilitating experimental handling (APExBIO).

This article extends prior analyses (SAR405 and the Vps34 Kinase Pathway) by integrating new benchmarks for selectivity and outlining direct comparison with mTOR axis inhibitors, which earlier reviews did not address. For an advanced perspective on workflow optimization, see SAR405 (SKU A8883): Enabling Reliable Autophagy Inhibition; here, we clarify the compound’s specificity and compatibility with live-cell imaging not fully explored by previous studies.

Common Pitfalls or Misconceptions

• SAR405 does NOT inhibit class I or II PI3Ks or mTOR at research-relevant concentrations (≤10 μM).
• It is ineffective in models where autophagy is independent of Vps34 signaling (e.g., alternative PI3K pathways).
• SAR405 is not a direct inhibitor of AMPK or ULK1; effects on these pathways are indirect and context-dependent (Park et al., 2023).
• The compound is unstable in aqueous buffers—use DMSO or ethanol (ultrasonic assistance) for dissolution; avoid long-term aqueous storage.
• Results in energy-stressed cells may be confounded by AMPK-ULK1 feedback loops, requiring careful experimental design.

Applications, Limits & Misconceptions

SAR405 is a valuable tool for studying autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment. Its high specificity enables mechanistic studies without off-target effects on other PI3K classes or mTOR. Applications include cancer research (e.g., tumor cell survival, chemoresistance), neurodegenerative disease models (e.g., protein aggregate clearance), and basic autophagy signaling pathway mapping (SAR405: Precision Vps34 Inhibition—this article provides a more granular analysis of experimental controls and selectivity). However, it is not suitable for dissecting autophagy events mediated by class I or II PI3Ks, nor for direct modulation of AMPK or ULK1 activity. Use is limited by compound solubility and stability in aqueous environments.

Workflow Integration & Parameters

• Recommended SAR405 stock concentration: >10 mM in DMSO; store at or below -20°C for several months (APExBIO).
• For working solutions, dilute in compatible media immediately before use; avoid repeated freeze-thaw cycles.
• Use ethanol only with ultrasonic assistance for dissolution; compound is insoluble in water.
• For cell-based assays, titrate SAR405 from 1 nM to 10 μM to determine optimal autophagy inhibition; monitor GFP-LC3 puncta or LC3-II accumulation as quantitative readouts.
• Combine with mTOR inhibitors (e.g., everolimus) to dissect dual pathway contributions to autophagy regulation.
• Refer to SAR405: Advanced Insights for practical guidance on integrating SAR405 into multi-parametric live-cell imaging workflows. This article complements by emphasizing compound handling and selectivity.

Conclusion & Outlook

SAR405 (A8883, APExBIO) is a validated, highly selective ATP-competitive inhibitor of Vps34, enabling precise modulation of autophagy and vesicle trafficking in mammalian cells. Its superior target specificity, robust solubility properties, and compatibility with combination studies (e.g., mTOR inhibition) make it a preferred tool for dissecting autophagy pathways in cancer and neurodegenerative disease research. Future studies should explore SAR405’s utility in complex in vivo models and further investigate its impact on energy stress responses and organelle crosstalk. For full reagent specifications and ordering, visit the official SAR405 product page.